AvenCell derives its name from the French word “avenir” to reflect the aim to be the FUTURE of cell therapy. AvenCell is building a truly transformative cell therapy company that targets difficult-to-treat cancers, with its lead programs focusing on acute myeloid leukemia (AML) and additional programs targeting other hematological malignancies. AvenCell was formed with the goal to create truly allogeneic cells that persist as long or longer than autologous therapies and develop a universal and switchable construct that allows complete control and target redirection of T cells after they are infused into a patient. Integration of these two platforms allows for complete separation of the manufacturing of cells from ultimate patient and cancer target, thus providing significant scalability potential at orders of magnitude more efficient than current approaches.
Learn more at avencell.com.
Learn more at avencell.com.
Location: United States, Massachusetts, Watertown
Total raised: $152M
Investors 2
| Date | Name | Website |
| 05.12.2024 | F-Prime Ca... | fprimecapi... |
| 23.01.2025 | Eight Road... | eightroads... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 30.06.2025 | Grant | $40M | - |
| 04.11.2024 | Series B | $112M | - |
Mentions in press and media 8
| Date | Title | Description |
| 30.06.2025 | AvenCell Awarded Up to $40 Million AMED Grant to Advance Allogeneic CAR-T Program | TOKYO, June 30, 2025 /PRNewswire/ -- AvenCell Japan, a wholly owned subsidiary of AvenCell Therapeutics, a private, clinical-stage biotechnology company developing best-in-class CAR-T therapies for hematologic cancers and autoimmune disease... |
| 04.11.2024 | AvenCell's $112 Million Leap: A New Dawn in Cell Therapy | AvenCell Therapeutics is on the rise. The Watertown, MA-based company has just secured $112 million in Series B funding. This financial boost is a game-changer. It promises to accelerate the development of innovative cell therapies aimed at... |
| 04.11.2024 | AvenCell: Clinical-Stage Cell Therapy Company Raises $112 Million (Series B) | AvenCell Therapeutics – a leading clinical-stage cell therapy company focused on advancing both autologous and allogeneic switchable CAR-T cell therapies – announced that it has raised $112 million in Series B funding. Global life sciences ... |
| 25.10.2024 | The Week’s 10 Biggest Funding Rounds: Seaport Therapeutics And Zip Top Big Money Week | 4 Shares Email Facebook Twitter LinkedIn Want to keep track of the largest startup funding deals in 2024 with our curated list of $100 million-plus venture deals to U.S.-based companies? Check out The Crunchbase Megadeals Board. This is a w... |
| 22.10.2024 | AvenCell Therapeutics Inks $112M Series B | WATERTOWN, MA, AvenCell Therapeutics today announced that it has raised $112 million in Series B financing. >> Click here for more funding data on AvenCell Therapeutics >> To export AvenCell Therapeutics funding data to PDF and... |
| 22.10.2024 | AvenCell secures $112M series B to flick 'switchable' CAR-Ts in the clinic | AvenCell Therapeutics has secured $112 million in series B funds as the Novo Holdings-backed biotech seeks clinical proof that it can generate CAR-T cells that can be turned “on” once inside a patient. The Watertown, Massachusetts-based com... |
| 22.10.2024 | AvenCell Raises $112M in Series B Funding | AvenCell, a Watertown, MA-based clinical-stage cell therapy company, raised $112M in Series B funding. The round was led by Novo Holdings. New investors F-Prime Capital, Eight Roads Ventures Japan, Piper Heartland Healthcare Capital and NYB... |
| - | AvenCell | - |